LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

1.25 5.93

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.23

Max

1.25

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+206.4% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. märts 2026

Turustatistika
By TradingEconomics
Turukapital	3.5M 129M
Eelmine avamishind	-4.68
Eelmine sulgemishind	1.25

Uudiste sentiment

By Acuity

50%

127 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. veebr 2026, 23:21 UTC

Omandamised, ülevõtmised, äriostud

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15. veebr 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15. veebr 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15. veebr 2026, 23:06 UTC

Tulu

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15. veebr 2026, 23:04 UTC

Tulu

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15. veebr 2026, 23:04 UTC

Tulu

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15. veebr 2026, 23:01 UTC

Tulu

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15. veebr 2026, 23:01 UTC

Tulu

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15. veebr 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15. veebr 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15. veebr 2026, 22:52 UTC

Omandamised, ülevõtmised, äriostud

Qube Shareholders to Receive A$5.20/Share in Cash

15. veebr 2026, 22:52 UTC

Omandamised, ülevõtmised, äriostud

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15. veebr 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO Tania Archibald Speaking on a Call With Media

15. veebr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15. veebr 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15. veebr 2026, 22:14 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15. veebr 2026, 22:14 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15. veebr 2026, 20:48 UTC

Tulu

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15. veebr 2026, 20:47 UTC

Tulu

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15. veebr 2026, 20:46 UTC

Tulu

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15. veebr 2026, 20:45 UTC

Tulu

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15. veebr 2026, 20:44 UTC

Tulu

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15. veebr 2026, 20:44 UTC

Tulu

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15. veebr 2026, 20:43 UTC

Tulu

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15. veebr 2026, 20:42 UTC

Tulu

BlueScope Net Debt A$2.2 Million at Dec. 31

15. veebr 2026, 20:42 UTC

Tulu

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15. veebr 2026, 20:41 UTC

Tulu

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15. veebr 2026, 20:40 UTC

Tulu

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15. veebr 2026, 20:40 UTC

Tulu

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15. veebr 2026, 20:39 UTC

Tulu

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

206.4% tõus

12 kuu keskmine prognoos

Keskmine 3.83 USD 206.4%

Kõrge 7 USD

Madal 2 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

127 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.